When switching from an originator biologic to a biosimilar for pediatric patients, making the choice can be complicated by the fact that most biologics research is performed in adults receiving the reference product.
Still, there are useful guideposts to follow, including some data on bioequivalence and also dilution and stability requirements that may point to the best formulary choice for a given institution. But for formulary managers who like to base such decisions on a strong